Recent Publications


2018

Prostate cancer in transgender women.

Ingham MD, Lee RJ, MacDermed D, Olumi AF.

Urol Oncol. 2018 Dec;36(12):518-525. doi: 10.1016/j.urolonc.2018.09.011. Epub 2018 Oct 12. Review. PMID: 30322726

Impact of Multifocality and Multilocation of Positive Surgical Margin After Radical Prostatectomy on Predicting Oncological Outcome.

Wu S, Lin SX, Wirth GJ, Lu M, Lu J, Subtelny AO, Wang Z, Dahl DM, Olumi AF, Wu CL.

Clin Genitourin Cancer. 2019 Feb;17(1):e44-e52. doi: 10.1016/j.clgc.2018.08.007. Epub 2018 Aug 30.

PMID: 30287224

BRCA1 Interacting Protein COBRA1 Facilitates Adaptation to Castrate-Resistant Growth Conditions.

Yun H, Bedolla R, Horning A, Li R, Chiang HC, Huang TH, Reddick R, Olumi AF, Ghosh R, Kumar AP.

Int J Mol Sci. 2018 Jul 20;19(7). pii: E2104. doi: 10.3390/ijms19072104. PMID: 30036938 

Metabolomic Prediction of Human Prostate Cancer Aggressiveness: Magnetic Resonance Spectroscopy of Histologically Benign Tissue.

Vandergrift LA, Decelle EA, Kurth J, Wu S, Fuss TL, DeFeo EM, Halpern EF, Taupitz M, McDougal WS, Olumi AF, Wu CL, Cheng LL.

Sci Rep. 2018 Mar 26;8(1):4997. doi: 10.1038/s41598-018-23177-w. PMID: 29581441 

PARP-1 inhibition with or without ionizing radiation confers reactive oxygen species-mediated cytotoxicity preferentially to cancer cells with mutant TP53.

Liu Q, Gheorghiu L, Drumm M, Clayman R, Eidelman A, Wszolek MF, Olumi A, Feldman A, Wang M, Marcar L, Citrin DE, Wu CL, Benes CH, Efstathiou JA, Willers H.

Oncogene. 2018 May;37(21):2793-2805. doi: 10.1038/s41388-018-0130-6. Epub 2018 Mar 7.

PMID: 29511347 

Metformin: an antiproliferative agent and methylation regulator in treating prostatic disease? 

Wang Z, Olumi AF. 

Am J Physiol Renal Physiol. 2018 Mar 1;314(3):F407-F411. doi: 0.1152/ajprenal.00443.2017. PMID: 29117997

Expression of aromatase in tumor related stroma is associated with human bladder cancer progression.

Wu S, Ye J, Wang Z, Lin SX, Lu M, Liang Y, Zhu X, Olumi AF, Zhong WD, Wu CL.

Cancer Biol Ther. 2018 Mar 4;19(3):175-180. doi: 10.1080/15384047.2017.1414762. PMID: 29303414

Estradiol signaling mediates gender difference in visceral adiposity via autophagy.

Tao Z, Zheng LD, Smith C, Luo J, Robinson A, Almeida FA, Wang Z, Olumi AF, Liu D, Cheng Z.

Cell Death Dis. 2018 Feb 22;9(3):309. doi: 10.1038/s41419-018-0372-9. PMID: 29472585


2017

Androgenic to Estrogenic Switch in Human Adult Prostate Gland is regulated by Epigenetic Silencing of Steroid 5-α Reductase 2

Wang Z, Hu L, Salari K, Bechis S, Ge R, Wu S, Rassoulian C, Pham J, Wu CL, Tabatabaei S, Strand D, Olumi AF. J Pathol. 2017 Dec;243(4):457-467. doi: 10.1002/path.4985.

Understanding temporal trends in medical costs associated with progression to metastatic prostate cancer.

Frendl DM, Olumi AF.

Cancer. 2017 May 23. doi: 10.1002/cncr.30779.

PMID: 28542736


Metformin inhibits the proliferation of benign prostatic epithelial cells.

Wang Z, Xiao X, Ge R, Li J, Johnson CW, Rassoulian C, Olumi AF.

PLoS One. 2017 Mar 2;12(3):e0173335. doi: 10.1371/journal.pone.0173335.

PMID: 28253329


2015

Designing a broad-spectrum integrative approach for cancer prevention and treatment.

Block KI, Gyllenhaal C, Lowe L, Wang Z, et al.

Semin Cancer Biol. 2015 Dec;35 Suppl:S276-304. doi: 10.1016/j.semcancer.2015.09.007. Review.

PMID: 26590477


Broad targeting of angiogenesis for cancer prevention and therapy.

Wang Z, Dabrosin C, Yin X, Fuster MM, Arreola A, Rathmell WK, Generali D, Nagaraju GP, El-Rayes B, Ribatti D, Chen YC, Honoki K, Fujii H, Georgakilas AG, Nowsheen S, Amedei A, Niccolai E, Amin A, Ashraf SS, Helferich B, Yang X, Guha G, Bhakta D, Ciriolo MR, Aquilano K, Chen S, Halicka D, Mohammed SI, Azmi AS, Bilsland A, Keith WN, Jensen LD.

Semin Cancer Biol. 2015 Dec;35 Suppl:S224-43. doi: 10.1016/j.semcancer.2015.01.001. Epub 2015 Jan 16. Review.

PMID: 25600295


Metformin represses cancer cells via alternate pathways in N-cadherin expressing vs. N-cadherin deficient cells.

Ge R, Wang Z, Wu S, Zhuo Y, Otsetov AG, Cai C, Zhong W, Wu CL, Olumi AF.

Oncotarget. 2015 Oct 6;6(30):28973-87. doi: 10.18632/oncotarget.5023.

PMID: 26359363  


Age and Obesity Promote Methylation and Suppression of 5α-Reductase 2: Implications for Personalized Therapy of Benign Prostatic Hyperplasia.

Bechis SK, Otsetov AG, Ge R, Wang Z, Vangel MG, Wu CL, Tabatabaei S, Olumi AF.

J Urol. 2015 Oct;194(4):1031-7. doi: 10.1016/j.juro.2015.04.079. Epub 2015 Apr 25.

PMID: 25916673  


Succinate dehydrogenase B: a new prognostic biomarker in clear cell renal cell carcinoma.

Cornejo KM, Lu M, Yang P, Wu S, Cai C, Zhong WD, Olumi A, Young RH, Wu CL.

Hum Pathol. 2015 Jun;46(6):820-6. doi: 10.1016/j.humpath.2015.02.013. Epub 2015 Mar 11.

PMID: 25827535  


Activation of AKR1C1/ERβ induces apoptosis by downregulation of c-FLIP in prostate cancer cells: A prospective therapeutic opportunity.

Yun H, Xie J, Olumi AF, Ghosh R, Kumar AP.

Oncotarget. 2015 May 10;6(13):11600-13.

PMID: 25816367  


DNA methyl transferase 1 reduces expression of SRD5A2 in the aging adult prostate.

Ge R, Wang Z, Bechis SK, Otsetov AG, Hua S, Wu S, Wu CL, Tabatabaei S, Olumi AF.

Am J Pathol. 2015 Mar;185(3):870-82. doi: 10.1016/j.ajpath.2014.11.020. Epub 2015 Feb 17.

PMID: 25700986


SATB1 overexpression regulates the development and progression in bladder cancer through EMT.

Wan F, Cheng C, Wang Z, Xiao X, Zeng H, Xing S, Chen X, Wang J, Li S, Zhang Y, Xiang W, Zhu Z, Johnson C, Zhu Z.

PLoS One. 2015 Feb 23;10(2):e0117518. doi: 10.1371/journal.pone.0117518. eCollection 2015.

PMID: 25706386


2014

 

Metformin use and prostate cancer risk.

Preston MA, Riis AH, Ehrenstein V, Breau RH, Batista JL, Olumi AF, Mucci LA, Adami HO, Sørensen HT.

Eur Urol. 2014 Dec;66(6):1012-20. doi: 10.1016/j.eururo.2014.04.027. Epub 2014 May 22.

PMID: 24857538  


Clinical features of leiomyosarcoma of the urinary bladder: analysis of 183 cases.

Rodríguez D, Preston MA, Barrisford GW, Olumi AF, Feldman AS.

Urol Oncol. 2014 Oct;32(7):958-65. doi: 10.1016/j.urolonc.2014.01.025. Epub 2014 Jul 11.

PMID: 25027684


5α-Reductase inhibitors and risk of high-grade or lethal prostate cancer.

Preston MA, Wilson KM, Markt SC, Ge R, Morash C, Stampfer MJ, Loda M, Giovannucci E, Mucci LA, Olumi AF.

JAMA Intern Med. 2014 Aug;174(8):1301-7. doi: 10.1001/jamainternmed.2014.1600.

PMID: 24887392


Personalized medicine for the management of benign prostatic hyperplasia.

Bechis SK, Otsetov AG, Ge R, Olumi AF.

J Urol. 2014 Jul;192(1):16-23. doi: 10.1016/j.juro.2014.01.114. Epub 2014 Feb 25. Review.

PMID: 24582540  


Prognostic significance of indeterminate lung nodules in renal cell carcinoma.

Xu R, Horick N, McGovern FJ, Dahl DM, Feldman AS, Blute ML, Olumi AF, Michaelson MD.

Urol Oncol. 2014 Apr;32(3):355-61. doi: 10.1016/j.urolonc.2013.09.001. Epub 2014 Jan 4.

PMID: 24397994  


Medical oncology consultation and minimization of overtreatment in men with low-risk prostate cancer.

Aizer AA, Paly JJ, Michaelson MD, Rao SK, Nguyen PL, Kaplan ID, Niemierko A, Olumi AF, Efstathiou JA.

J Oncol Pract. 2014 Mar;10(2):107-12. doi: 10.1200/JOP.2013.000902. Epub 2014 Jan 7.

PMID: 24399853


Expression of variant isoforms of the tyrosine kinase SYK determines the prognosis of hepatocellular carcinoma.

Hong J, Yuan Y, Wang J, Liao Y, Zou R, Zhu C, Li B, Liang Y, Huang P, Wang Z, Lin W, Zeng Y, Dai JL, Chung RT.

Cancer Res. 2014 Mar 15;74(6):1845-56. doi: 10.1158/0008-5472.CAN-13-2104. Epub 2014 Jan 29.

PMID: 24477596


Inhibition of PP2A activity confers a TRAIL-sensitive phenotype during malignant transformation.

Yang H, Chen X, Wang X, Li Y, Chen S, Qian X, Wang R, Chen L, Han W, Ruan A, Du Q, Olumi AF, Zhang X.

Mol Cancer Res. 2014 Feb;12(2):217-27. doi: 10.1158/1541-7786.MCR-13-0441. Epub 2013 Dec 2.

PMID: 24296757





Commentary on "identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array." Eeles RA et. al.

Olumi AF.

Urol Oncol. 2014 Feb;32(2):211. doi: 10.1016/j.urolonc.2013.08.019.

PMID: 24445293




Quantization and diagnosis of Shanghuo (Heatiness) in Chinese medicine using a diagnostic scoring scheme and salivary biochemical parameters.

Liu S, Huang Z, Wu Q, Huang Z, Wu L, Yan W, Chang DL, Yang Z, Wang Z.

Chin Med. 2014 Jan 4;9(1):2. doi: 10.1186/1749-8546-9-2.

PMID: 24386887


Primary spermatic cord tumors: disease characteristics, prognostic factors, and treatment outcomes.

Rodríguez D, Barrisford GW, Sanchez A, Preston MA, Kreydin EI, Olumi AF.

Urol Oncol. 2014 Jan;32(1):52.e19-25. doi: 10.1016/j.urolonc.2013.08.009. Epub 2013 Nov 13.

PMID: 24239475


2013

Models of care and NCCN guideline adherence in very-low-risk prostate cancer.

Aizer AA, Paly JJ, Zietman AL, Nguyen PL, Beard CJ, Rao SK, Kaplan ID, Niemierko A, Hirsch MS, Wu CL, Olumi AF, Michaelson MD, D'Amico AV, Efstathiou JA.

J Natl Compr Canc Netw. 2013 Nov;11(11):1364-72.